Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Lancet
M A DimopoulosS Z Usmani

Abstract

Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in combination with daratumumab has shown substantial efficacy with tolerable safety in relapsed or refractory multiple myeloma in a phase 1 study. In this study, we aimed to compare the efficacy and safety of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. In this randomised, multicentre, open-label, phase 3 study, 466 patients recruited from 102 sites across North America, Europe, Australia, and Asia with relapsed or refractory multiple myeloma were randomly assigned 2:1 to carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd). All patients received twice per week carfilzomib at 56 mg/m2 (20 mg/m2; days 1 and 2 during cycle 1). Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cycle 1 and at 16 mg/kg weekly for the remaining doses of the first two cycles, then every 2 weeks for four cycles (cycles 3-6), and every 4 weeks thereafter. Patients received 40 mg dexamethasone weekly (20 mg for patients ≥75 years old starting ...Continue Reading

Citations

Aug 5, 2020·Expert Opinion on Biological Therapy·Barry PaulSaad Z Usmani
Sep 25, 2020·Expert Review of Anticancer Therapy·Kathryn T MaplesR Donald Harvey
Sep 23, 2020·BMJ : British Medical Journal·Urvi A Shah, Sham Mailankody
Nov 11, 2020·Journal of Hematology & Oncology·Yang YangZhen Cai
Dec 4, 2020·Cancers·Mario A LegardaJavier de la Rubia
Jan 8, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kishan K PatelScott F Huntington
Jan 22, 2021·Arteriosclerosis, Thrombosis, and Vascular Biology·Chi Keung Lam, Joseph C Wu
Sep 22, 2020·Panminerva Medica·Federico VozellaClaudio Cerchione
Nov 4, 2020·International Journal of Molecular Sciences·Mattia D'AgostinoSara Bringhen
Jan 9, 2021·Frontiers in Oncology·Alessandro GozzettiMonica Bocchia
Nov 8, 2020·Journal of Clinical Medicine·Hélène GardeneyStéphanie Guidez
Mar 4, 2021·Current Oncology·Synat KangLi Yu
Mar 11, 2021·BMJ Case Reports·Dale SeviarDavid Howlett
Mar 18, 2021·Current Hematologic Malignancy Reports·Hitomi Hosoya, Surbhi Sidana
Mar 23, 2021·British Journal of Haematology·Omar Nadeem, Paul G Richardson
Mar 27, 2021·Expert Review of Hematology·Marc BraunsteinFaith Davies
Apr 3, 2021·Therapeutic Advances in Hematology·Larysa SanchezJoshua Richter
Apr 4, 2021·Cancers·Raquel LopesCristina João
May 1, 2021·Journal of Personalized Medicine·Christopher Chang-Yew Leow, Michael Sze Yuan Low
May 19, 2021·JCO Oncology Practice·Meera MohanBinod Dhakal
May 20, 2021·American Society of Clinical Oncology Educational Book·Jessica CaroFaith E Davies
May 20, 2021·American Society of Clinical Oncology Educational Book·Nitya NathwaniAmrita Krishnan
Jun 3, 2021·Cancers·Fredrik Schjesvold, Albert Oriol
Jun 10, 2021·Therapeutic Advances in Hematology·Albert OriolJosep-Maria Ribera

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.